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Abstract
Background: Clostridium botulinum, an obligate anaerobic spore-forming bacterium, produces seven antigenic
variants of botulinum toxin that are distinguished serologically and termed “serotypes”. Botulinum toxin blocks the
release of acetylcholine at neuromuscular junctions resulting in flaccid paralysis. The potential lethality of the
disease warrants a fast and accurate means of diagnosing suspected instances of food contamination or human
intoxication. Currently, the Food and Drug Administration (FDA)-accepted assay to detect and type botulinum
neurotoxins (BoNTs) is the mouse protection bioassay. While specific and sensitive, this assay requires the use of
laboratory animals, may take up to four days to achieve a diagnosis, and is unsuitable for high-throughput analysis.
We report here a two-step PCR assay that identifies all toxin types, that achieves the specificity of the mouse
bioassay while surpassing it in equivalent sensitivity, that has capability for high-throughput analysis, and that
provides quantitative results within hours. The first step of our assay consists of a conventional PCR that detects
the presence of C. botulinum regardless of the neurotoxin type. The second step uses quantitative PCR (qPCR)
technology to determine the specific serotype of the neurotoxin.
Results: We assayed purified C. botulinum DNA and crude toxin preparations, as well as food and stool from
healthy individuals spiked with purified BoNT DNA, and one stool sample from a case of infant botulism for the
presence of the NTNH gene, which is part of the BoNT gene cluster, and for the presence of serotype-specific
BoNT genes. The PCR surpassed the mouse bioassay both in specificity and sensitivity, detecting positive signals in
BoNT preparations containing well below the 1 LD50 required for detection via the mouse bioassay. These results
were type-specific and we were reliably able to quantify as few as 10 genomic copies.
Conclusions: While other studies have reported conventional or quantitative PCR-based assays for the detection of
C. botulinum genes, our procedure’s high-throughput capability and its portability allows most laboratories to
quickly assess the possible presence of BoNTs either in food processing samples or in suspected cases of botulism.
Thus, this assay provides rapid and specific detection of BoNT and toxin complex genes and would enable the
targeting of appropriate therapeutics to infected individuals in a timely manner.
Background
Clostridium botulinum, an obligate anaerobic spore-
forming bacterium, produces botulinum neurotoxin
(BoNT), the most potent toxin known [1-3]. BoNT is
classified as a Category A biothreat agent by the Centers
for Disease Control and Prevention (CDC) because of
its lethality and ease of production, transport and disse-
mination [4,5]. In addition, BoNT poses several threats
to the public health: first, the possibility of foodborne
botulism represents a major potential health hazard that
requires continual monitoring by the food industry. Sec-
ond, infant botulism has been the most common form
of human botulism in the United States for more than
20 years and hospitalizes approximately 80-100 U.S.
infants annually [6]. Third, cases of wound botulism due
to intravenous drug use continue to increase [7,8].
Botulism toxicity results from one of seven serologi-
cally distinct neurotoxins (types A-G) that cause a
severe neuroparalytic disease characterized by descend-
ing flaccid paralysis [9]. Rarely, unique strains of
C. butyricum and C. baratii may also cause human
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and F, respectively [10,11]. The toxin acts by binding to
peripheral cholinergic nerve endings and inhibiting
release of acetylcholine at the neuromuscular junction.
A part of the toxin is a zinc-dependent protease that
cleaves target substrate proteins (SNAREs), located
either on the plasma membrane or the synaptic vesicle,
thereby preventing their binding, fusion and release of
neurotransmitter. BoNTs cleave specific amino acids on
the target proteins of the SNARE complex. BoNT/A and
BoNT/E act on SNAP-25, while BoNT/C targets syn-
taxin as well as SNAP-25. The remaining toxin types
(BoNT/B, BoNT/D, BoNT/E and BoNT/F) all act on
synaptobrevin, but at different cleavage sites [12-15].
The potential severity and lethality of the disease war-
rants sensitive and specific detection and serotyping of
toxin and its typing to enable correct administration of
serotype-specific antitoxin in a timely manner. Although
treatment with Human Botulism Immune Globulin
(BabyBIG®) or equine antitoxin is based on clinical find-
ings and should be instituted as rapidly as possible
[5,16,17], definitive microbiological diagnosis may take
several days or even longer. This extended time to diag-
nosis occurs because detection of the bacterium and its
toxin relies on toxicity assessment in mice (the mouse
protection bioassay) and lengthy culture assays, which,
while sensitive and specific, may be time-consuming and
difficult [18,19]. Moreover, the availability of the mouse
protection bioassay is limited due to lack of animal facil-
ities and reagent constraints.
A readily available rapid diagnostic test would be valu-
able for public health and medical management of food-
borne, infant, wound, or bioterrorist botulism outbreaks.
Quick, accurate diagnosis would enable the limited sup-
ply of equine or human antitoxin to be directed to
affected patients, thereby allowing exposed but
unaffected individuals to be reassured and spared unne-
cessary treatment with an equine serum product. A
high-throughput assay would also be beneficial to the
food industry, where the use of large quantities of mice
is impractical.
Several studies have described PCR-based assays that
detect the various serotypes of BoNT genes [20-26].
With the advent of quantitative PCR (qPCR), further
studies have reported assays that detect the toxin types
(A, B, E and F) generally implicated in human illness
and food contamination [27-31]. However, comprehen-
sive sequence analysis shows a high level of genetic
variability within the toxin types that enables differentia-
tion of toxin types into subtypes [32,33]. Thus, existing
assays may not reliably detect all known subtype var-
iants within each botulinum toxin type.
For these reasons we have developed a novel two-
step PCR-based assay that can detect both BoNT and
other gene sequences located within the toxin gene
complex. It is known that C. botulinum DNA is readily
attracted to botulinum neurotoxins, necessitating the
use of various treatments for the removal of nucleic
acids during toxin purification [34-37]. These DNA
sequences may be found even in highly purified pro-
tein preparations of the toxin and are therefore a reli-
able surrogate for the presence of BoNT, enabling
rapid detection without using mice. As antitoxin doses
are administered based on the serotype of toxin and
clinical symptoms and not on the amount of active
toxin present in the sample, the assay described here
will provide the critical information needed for clini-
cians to treat affected patients. The first step in this
procedure is a universal electrophoresis-based PCR
that detects the presence of the C. botulinum non-
toxin-nonhemagglutinin (NTNH) gene, a highly con-
served toxin complex gene that is found in all
C. botulinum toxin types and subtypes that has been
found in all BoNT-producing C. botulinum gene
sequences examined to date [32,38]. Thus, samples
that contain BoNT can be identified irrespective of ser-
otype, thereby providing comprehensive but not type-
specific detection. A similar independent assay to
detect NTNH has recently been reported by Rafael and
Andreadis [38]. The second step of the assay uses
qPCR to determine quantitatively the specific BoNT
toxin type by using seven different degenerate primer/
probe pairs, one for each of the seven A-G toxin sero-
types. These assays successfully detected toxin genes
from 22 of the 26 known toxin subtypes.
Results
Universal detection of the C. botulinum toxin complex
gene NTNH
Figure 1A shows the C. botulinum neurotoxin complex
gene organization for each type [39,40] and the primers
designed for the nontoxin-nonhemagglutinin gene
(NTNH) (Figure 1B), which is present in all C. botuli-
num types directly upstream from the neurotoxin gene
in BoNT toxin gene clusters. The primers target an area
that is highly conserved between C. botulinum types A-
G. Degenerate primers were designed to accommodate
any base discrepancy in the target area.
We tested these primers with DNA purified from
C. botulinum cultures of each toxin type and also
included control genomic and plasmid DNA from sam-
ples of E. coli bacterial colonies (DH5a) as well as crude
lysate from human peripheral blood mononuclear cells.
A specific NTNH product of 101 base pairs was
detected in each lane containing clostridial DNA repre-
senting all toxin serotypes as well as BoNT-producing
C. butyricum and C. baratii isolates, but no band was
detected in any of the controls.
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was specific to BoNT-producing clostridial species.
Table 1 shows the results of the universal PCR per-
formed with DNA purified from clostridial species har-
bouring the BoNT gene and those lacking these genes.
A strong PCR product was detected from all samples
that expressed detectable levels of BoNTs, but not from
any clostridial strain that did not produce BoNTs.
We next confirmed the robustness of NTNH detec-
tion both on food samples that were spiked with puri-
fied serotype-specific C. botulinum DNA and on crude
toxin preparations. Canned vegetables and canned meat
were spiked with 100 μL of purified DNA at dilutions
down to 1 genomic copy of type-specific BoNT DNA in
100 μL. DNA was extracted from spiked samples as
described in the methods section. Only samples that
had been spiked with clostridial DNA from neurotoxin-
containing strains tested positive for NTNH (data not
shown). As with the food samples, DNA was extracted
from crude toxin-containing cultures and tested for the
presence of NTNH. All of the purified DNA samples
and most of the crude culture supernatant samples
examined were positive for NTNH (Table 1). The lack
of amplification from some of the crude culture super-
natants may be due to lack of DNA extraction resulting
in the presence of proteinaceous PCR inhibitors.
In addition to spiking food, we also spiked healthy
infant stool with varying concentrations of BoNT sero-
type-specific C. botulinum DNA as described in the
materials and methods. We detected a positive PCR
result in all samples of stool spiked with BoNT DNA to
an amount as low as an equivalent of 10 genomic
copies. In the sample spiked with BoNT A at an equiva-
lent of 1 genomic copy, we obtained a weak positive
PCR result. Additionally, we tested DNA extracted from
a clinical sample from a recent case of infant botulism,
diagnosed by the mouse protection bioassay, and clearly
detected presence of the NTNH gene (Table 2).
Quantitative type-specific detection of C. botulinum
We designed primers and probes specific to each toxin
type (A-G). Each set targets portions of the light chain
of the neurotoxin gene in areas conserved within each
subtype yet unique to each toxin type such that no
Figure 1 Selection and design of universal PCR primers. (A) Diagram of C. botulinum neurotoxin gene (BoNT) organization (adapted from
Chen et al. 2007) [39]. (B) Non-toxin non-hemagglutinin gene (NTNH) primers targeting a highly conserved area directly upstream from BoNT.
Primer sequences contain degenerate bases to accommodate all strain variation.
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between strains were accounted for by incorporation of
degenerate bases (Table 3). As validation, Figure 2
shows results of the type-specific qPCR performed on
the plasmid standards corresponding to each C. botuli-
num. Not only was each primer/probe set able to detect
its C. botulinum type toxin gene sequence sensitively
and specifically, there was also no cross-reactivity of any
primer/probe set with a toxin gene sequence from a dif-
ferent C. botulinum type.
Figure 3 shows quantitative type-specific amplification
of DNA purified from laboratory-cultured samples of
C. botulinum representing all toxin types A-G. Each pri-
mer/probe set amplified only that DNA of the specific
toxin gene type with no amplification of toxin gene
sequences of a differing type. As confirmation of our
assay, we diluted purified DNA from C. botulinum cul-
tures taking into account genomic size and concentra-
tion of the DNA preparation. We made 5 ten-fold
dilutions representing 10
5 to one genomic copies of
BoNT and tested six replicate reactions per assay. Figure
3 (table) shows that the sensitivity of detection is consis-
tently as low as 10 gene copies per reaction. Using our
plasmid standards, actual values consistently showed
Table 1 NTNH gene detection on C. botulinum and other clostridial strains
BoNT subtype strain PCR(DNA)
a (culture supernatant)
b other clostridia strain PCR(DNA)
a
A1 Hall + + C. absonum ATCC 27555 -
A1 CDC 1757 + + C. baratii
e ATCC 27638 -
A1 CDC 1744 + + C. bifermentans ATCC 638 -
A2 Kyoto-F + + C. haemolyticum ATCC 9650 -
A2b CDC 1436 + + C. hastiforme ATCC 25772 -
A3 Loch Maree + + C. histolyticum ATCC 19401 -
B1 Okra + + C. novyi ATCC 17861 -
B1 CDC 1656 + + C. novyi ATCC 19402 -
B1 CDC 1758 + + C. novyi A ATCC 19402 -
B2 213B + + C. novyi B ATCC 2706 -
B2 CDC 1828 + + C. perfringens A ATCC 3624 -
B4 (npB) Eklund 17B + + C. perfringens A ATCC 12915 -
Ba4 CDC 657 + + C. perfringens A ATCC 12917 -
Bf An436 + + C. perfringens A ATCC 12918 -
C Stockholm + - C. perfringens A ATCC 12919 -
C/D 6813 + - C. perfringens A ATCC 13124 -
D ATCC 11873 + + C. perfringens B ATCC 3626 -
D 1873 + nd C. perfringens D ATCC 3629 -
D/C VPI 5995 + + C. perfringens D ATCC 3630 -
E1 Beluga + - C. perfringens D ATCC 3631 -
E2 CDC 5247 + nt C. perfringens D ATCC 12920 -
E2 CDC 5906 + nt C. perfringens E ATCC 27324 -
E3 Alaska E43 + + C. ramosum ATCC 25582 -
E4 (It butyr)
c BL5262 + - C. septicum ATCC 12464 -
F1 (prot) Langeland + + C. sordelli ATCC 9714 -
F2 (np) Eklund 202F + - C. sporogenes ATCC 19404 -
F3 (baratii)
d Orange + nt C. sporogenes ATCC3854 -
G 1354 + nd C. subterminale ATCC 25774 -
C. tertium ATCC 14573 -
C. tetani ATCC 10799 -
C. tetani ATCC19406 -
a+/- indicates presence/absence of 101 bp band on agarose gel. Samples are purified DNA from bacterial cultures as described in the Methods section.
bSamples originate from filtered culture supernatants containing crude toxin. +/- indicates presence/absence of 101 bp band on agarose gel. nd = not detected,
nt = not tested.
cBoNT E-producing strain of C. butyricum isolated from an infant case in Italy.
dBoNT F-producing strain of C. baratii.
eNon-toxin producing strain of C, baratii.
Results from conventional PCR detection of NTNH. A (+/-) indicates presence/absence of 101 bp band by agarose gel, respectively. DNA results indicate PCR
detection of NTNH in purified DNA from both C botulinum and other Clostridial strains. Culture supernatant results indicate amplification of DNA within crude
culture supernatants. NT indicates samples that were not tested.
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and were reproducible in each replicate reaction. We
were able to detect 1 copy of the BoNT gene in several
toxin samples, but the overall detection level of our
assay was reliably as few as 10 copies of neurotoxin
gene.
To confirm the specificity of the assay, we further
extracted DNA from pure laboratory-cultures from
twenty-nine C. botulinum strains representing twenty-
two different toxin subtypes. Amplification occurred
only when DNA from a particular BoNT serotype was
paired with its type-specific primer/probe set, and there
was no cross-reactivity between primer/probe sets of
one serotype and toxin genes of a different serotype
(Table 4). Importantly, strains known to produce or
contain the genes for two toxin serotypes were success-
fully confirmed as such by the assay (Figure 4).
We then tested DNA-spiked food samples and crude
culture supernatants for the presence of serotype-speci-
fic BoNT genes using the above assays. In spiked food
samples, we were able to detect type-specific BoNT
DNA down to at least three genomic copies of BoNT
DNA in each sample (Figure 5A and 5B). To determine
relative levels of detections, we tested the four major
causes of foodborne botulism, BoNT A, B, E, and F
within crude toxin supernatants. Positive PCR signals
were seen with sample dilutions containing toxin con-
centrations of 0.000018 LD50 BoNT/A per ml and
0.00385 LD50 BoNT/B toxin per ml. The level of detec-
tion is greater than 50,000 times more sensitive than the
mouse bioassay for BoNT/A and greater than 250 times
m o r es e n s i t i v et h a nt h em o u s eb i o a s s a yf o rB o N T / Bi n
equivalent samples. Positive PCR signals were observed
with sample dilutions equal to 1LD50 in BoNT/E toxin/
mL and 0.007 LD50 BoNT/F toxin/mL. Thus the level of
detection for BoNT/E and BoNT/F matched or was
1000 times more sensitive than the mouse protection
bioassay, respectively (Table 5).
Next, we did comparative testing of crude culture
supernatants (without DNA extraction) against purified
DNA preparations from the same strains. As the crude
culture supernatants contained botulinum neurotoxins,
they were tested at an independent location that is
registered for the use of botulinum neurotoxins using
alternative equipment (the Roche Light Cycler versus
the ABI 7700 for the purified DNA preparations). All 23
BoNT-containing samples tested positive for the appro-
priate toxin subtype, including three samples containing
multiple toxin serotypes (A2b, Ba4, and Bf). In addition,
the mosaic C/D and D/C strains had positive PCR sig-
nals for both serotype C and D, confirming the exis-
tence of both BoNT/C and/D gene sequences in these
strains. The results, shown in Table 6, indicate that this
assay is equally effective at detecting and identifying
BoNT genes regardless of the sample (crude culture
supernatants or purified DNA preparations) or the
equipment used.
With the same DNA preparations described in the
previous section from healthy infant stool spiked with
C. botulinum DNA, we were able to detect type-specific
Table 2 NTNH PCR detection in spiked healthy infant
stool and a clinical infant botulism sample
Strain (genomic copies) NTNH Detection
BoNT A (10
4)+ +
BoNT A (10
2)+ +
BoNT A (10) +
BoNT A (1) +
BoNT B (10
4)+ +
BoNT B (10
2)+
BoNT B (10) +
BoNT B (1) -
BoNT C (10
4)+ +
BoNT C (10
2)+
BoNT C (10) +
BoNT C (1) -
BoNT D (10
4)+ +
BoNT D (10
2)+
BoNT D (10) -
BoNT D (1) -
BoNT E (10
4)+ +
BoNT E (10
2)+
BoNT E (10) +
BoNT E (1) -
BoNT F (10
4)+ +
BoNT F (10
2)+ +
BoNT F (10) +
BoNT F (1) -
BoNT G (10
4)+ +
BoNT G (10
2)+ +
BoNT G (10) +
BoNT G (1) -
Clinical stool sample ++
++ Denotes strong PCR band.
+ Denotes weak PCR band.
- Denotes no PCR Band.
Listed in this table are results from NTNH gene detection within spiked
samples of a healthy infant stool sample as described in the materials and
methods. Also included is the result from a confirmed case of infant botulism
in California. (++) indicates a strong positive PCR product at the dilution
tested, (+) is a weak positive PCR product, and (-) indicates no amplification
detected.
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BoNT DNA at the equivalent of 10,000 genomic copies.
The stool sample from the confirmed case of infant
botulism yielded a positive result with 1650 BoNT/A
specific gene copies detected in 5 μL of DNA extracted
from the stool sample (Table 7). This confirms the
result that had been obtained in the mouse protection
bioassay that had been performed for clinical diagnosis.
Discussion
The spectre of bioterrorist use of botulinum toxin pre-
sents a new and real danger to public health [4,41], and
in such an event a sensitive, specific and rapid diagnos-
tic assay to detect the presence of the bacterium and/or
its toxin will be needed. In addition, the possibility of
botulinum toxin contamination of manufactured food
requires constant monitoring. Indeed, over 90 different
food products have been recalled in 2007 due to botuli-
num toxin contamination http://www.cdc.gov/botulism/
botulism.htm. The current gold-standard assay, the
mouse protection bioassay, is impractical in situations
needing high-throughput analysis of multiple samples
possibly at multiple geographical locations. In 2003 the
National Institute of Allergy and Infectious Disease
(NIAID) issued recommendations for new assays needed
to detect botulism (NIAID Expert Panel on Botulism
Diagnostics, Bethesda Maryland, May 2003). These
recommendations stated that any new assay should be
“universal”, should be able to detect variants of all toxin
types, should be type-specific to determine proper anti-
toxin treatment, and should be sensitive and quantitative
to determine risk assessment.
Various methods that have been reported to address
these requirements include immunological assays such
as ELISA, ECL western blotting and Immuno-PCR,
enzymatic assays such as EndoPEP assays and molecular
techniques such as PCR [42-47]. The assays developed
t h u sf a ro f f e ram o r er a p i dm e a n so fd i a g n o s i n gb o t u -
lism, but each also has limitations in such areas as sam-
ple throughput, cost, inability to distinguish toxin types,
ease of use and false negative results [18,48].
PCR is a valuable methodology because it is sensitive,
specific, cost-effective, portable, automatable, and high-
throughput. However, PCR methods have certain limita-
tions, such as the inability to distinguish between biolo-
gically active toxin genes and silent toxin genes in the
bacterium [18]. While this is an important limitation as
it is the protein toxin rather than the DNA encoding it
that poses the threat, this is a rare occurrence since
complete loss of toxicity in C. botulinum strains is
Table 3 Primer and probe sets for each serotype used in quantitative PCR
Toxin Class Sequence Location on Toxin Gene(bp)
BoNT A Forward TGGTTTTGAGGAGTCACTTGAA 582
BoNT A Reverse TCATGTCCCCCAAATGTTCT 809
BoNT A Probe TGCAGGCAAATTTGCTACAGATCCA 627
BoNT B Forward CAAGAAAACAAAGGCGCAAG 619
BoNT B Reverse CTGGGATCTTGYCCTCCAAA 833
BoNT B Probe CGTGGATATTTTTCAGATCCAGCCTTG 652
BoNT C Forward CAACTTTAATTATTCAGATCCTGTTGA 18
BoNT C Reverse GGCTTGTAACTCGAGGAGGTT 199
BoNT C Probe TGAGCCTGAAAAAGCCTTTCGCA 93
BoNT D Forward CCATCATTTGAAGGGTTTGG 541
BoNT D Reverse TGGGTCCATCTTGAGARAAA 791
BoNT D Probe GATTCGTCCACAAGTTAGCGAGGGA 744
BoNT E Forward ATAATGGGAGCAGAGCCTGA 448
BoNT E Reverse CCCTTTAGCCCCATATAGTCC 678
BoNT E Probe TGCCAAGCAATCACGGTTTTGG 515
BoNT F Forward GTSAGACAATACCTCAAATATCAAATCG 1488
BoNT F Reverse CTGGYACTTTTTGTGCATGT 1646
BoNT F Probe TGCCAAGATATGATTCTAATGGAA 1551
BoNT G Forward ATCCAACCTGGAGCTGAAGA 427
BoNT G Reverse GCTGGATCTGCAAAATACGC 674
BoNT G Probe TGGCCATTCCCCAATATCAGAAGG 534
Y=Co rT
R=Ao rG
S=Go rC
Indicated in this table are the type specific primers and probes for each BoNT tested in this manuscript. Included are forward, reverse and probe sequences and
their locations within the toxin gene. Bases indicated in bold represent degenerate bases: Y represents C or T; S represents C or G, and R represents A or G.
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Page 6 of 16Figure 2 qPCR validation of plasmid standards. Each standard dilution tested against type-specific primers and probes and cross-checked
with primers and probes specific to all remaining types. Five ten-fold serial dilutions tested with each appropriate primer and probe set are
depicted in each amplification plot. All reactions amplified with non-type-specific primer and probe sets show no amplification and are
represented in bottom right amplification plot.
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Page 7 of 16Figure 3 qPCR detection of type-specific neurotoxin DNA. Each toxin type DNA amplified with type-specific primers and probes. Assay
sensitivity is shown in the table. Each toxin type DNA was amplified with its cognate primer and probe set. The DNA was diluted based on its
concentration and genomic size such that each reaction contained a known number of DNA target gene copies. Dilutions ran from 10
5
genomic copies to 1 genomic copy. Each dilution series was run with six replicates to determine reproducibility. Plasmid standards were
amplified along with each dilution series to determine exact copy number in each reaction. Results represent the percentage of the six
replicates that contained accurate copy numbers in each reaction.
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contain toxin complex genes (personal observations of
the co-authors) [49-51]. However, the consistent pre-
sence of C. botulinum DNA in even highly purified
toxin preparations can serve as a surrogate marker and
indicate the presence of toxin when C. botulinum con-
tamination is suspected (T. Smith, unpublished data).
Several different PCR methods have been reported, ran-
ging from conventional electrophoresis-based PCR,
including multiplex PCR, to real-time PCR and probe
hybridization [20,23,27,28,38,48,52,53]. Each PCR-based
method is reportedly faster and cheaper than the stan-
dard mouse protection bioassay [23]. However, most
PCR assays detect a narrow range of toxin types, notably
A, B, E and/or F, and do not consider the known
genetic variation (subtypes) within each particular toxin
type [32,33,54,55]. Botulinum neurotoxins, and their
genes, exhibit an extreme amount of variability. Cur-
rently, there have been over 26 toxin subtypes identified.
These toxin subtypes vary by ~1-32% at the amino acid
level and their genes vary by approximately the same
percentage at the nucleotide level. Despite this variabil-
ity, we have been able to successfully detect and cor-
rectly identify the serotypes from samples representing
22 of these toxin subtypes.
In our study, we also use PCR technology to detect
BoNT DNA in samples attempting to match the mouse
protection bioassay in sensitivity and specificity. Our
results show that we do surpass the sensitivity and spe-
cificity of the mouse protection bioassay in purified
DNA when parallel samples of known toxicity and/or
BoNT serotype are tested.
We detect BoNT DNA in samples reliably down to
ten genomic copies in all strains of each subtype tested.
In addition, our assay identified both toxins associated
with our bivalent strains, while initial testing using the
mouse bioassay only identified the predominant toxin in
each case. The PCR assay also differentiated mosaic C/D
and D/C strains from parental C and D strains; other
methodologies are unable to differentiate these subtypes.
With respect to the lower sensitivity of BoNT E detec-
tion, the data suggest that the initial genomic load of
BoNT E DNA was lower than that of other subtypes.
Based on the sensitivity of the assay presented here,
BoNT E DNA of the same initial genomic load as the
other subtypes tested will exhibit the same sensitivity
surpassing the mouse protection bioassay.
Based on previous work to detect the presence of
microbial 16S ribosomal DNA in human plasma samples
during human immunodeficiency virus (HIV) infection
to determine microbial translocation, we were able to
determine the presence of bacterial DNA in human
plasma using similar extraction and quantitative PCR
techniques as described here [56]. Clearly, when dealing
with clinical samples such as stool in which PCR inhibi-
tors may present a challenge in detection of the BoNT
DNA genes, there was a decrease in the detection limit
of spiked healthy infant stool sample. However, in test-
ing a confirmed infant botulism case in which the DNA
tested was obtained from stool, we were readily able to
determine the presence of the NTNH gene as well as its
type and concentration.
Conclusions
The two-step PCR assay described here fulfils the cri-
teria recommended by the NIAID expert panel [57].
The first step, universal PCR detects the NTNH toxin
complex gene that is conserved in all C. botulinum
strains. The NTNH gene can be used as a high-through-
put screening tool to determine those samples or
Table 4 Cross reactivity and specificity of primers and
probes with all subtypes of C. botulinum Subtype Specific
Primer and Probe set Used in Real Time PCR
BoNT subtype strain A B C D E F G
A1 Hall + - - - - - -
A1 CDC 1757 + - - - - - -
A1 CDC 1744 + - - - - - -
A2 Kyoto-F + - - - - - -
A2b CDC 1436 + + - - - - -
A3 Loch Maree + - - - - - -
B1 Okra - + - - - - -
B1 CDC 1656 - + - - - - -
B1 CDC 1758 - + - - - - -
B2 213B - + - - - - -
B2 CDC 1828 - + - - - - -
B3 CDC 795 - + - - - - -
B4 (npB) Eklund 17B - + - - - - -
Ba4 CDC 657 + + - - - - -
Bf An436 - + - - - - -
C Stockholm - - + - - - -
C/D 6813 - - + - - - -
D ATCC 11873 - - - + - - -
D 1873 - - - + - - -
D/C VPI 5995 - - - + - - -
E1 Beluga - - - - + - -
E2 CDC 5247 - - - - + - -
E2 CDC 5906 - - - - + - -
E3 Alaska E43 - - - - + - -
E4 (It butyr) BL5262 - - - - + - -
F1 (prot) Langeland - - - - - + -
F2 (np) Eklund 202F - - - - - + -
F3 (baratii) Orange - - - - - + -
G 1354 - - - - - - +
“+/-” indicates amplification/no amplification by real time PCR.
Indicated in the table are all strains tested with each type-specific BoNT
primer and probe set. A (+/-) indicates amplification/no amplification by real
time PCR.
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Page 9 of 16Figure 4 Detection of silent genes in dual BoNT containing strains of C. botulinum. Shown are amplification plots of three strains of
C. botulinum that contain silent genes: CDC1436 A2b (A), strain 657 Ba4 (B), and strain An436 Bf (C). Copy numbers and the indicated gene
detected by color are listed for each.
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Page 10 of 16individuals contaminated or infected with C. botulinum
regardless of the type. The second step qPCR is used to
determine the specific toxin type present and to esti-
mate the extent of contamination by determining the
gene load in each sample. A measure of the BoNT gene
load may be helpful to the food industry to detect the
presence and extent of contamination. Although the
BoNT gene load may not predict the severity of illness,
a fast, sensitive, and specific toxin detection assay will
enable prompt administration of appropriate antitoxin
therapy and assessment of the public health risk from
suspect foods. With this assay’s high-throughput cap-
ability and its portability, any laboratory may use it to
assess quickly the possible presence of BoNTs either in
food processing samples or in suspected cases of
botulism. Thus, this assay provides rapid and specific
detection of BoNT and toxin complex genes and would
enable the targeting of appropriate therapeutic agents
(eg: BabyBig® or equine antitoxin) to infected individuals
in a timely manner.
Methods
Bacterial strains and DNA purification
All strains tested within this report are listed in Table 8.
DNA used in each PCR test was extracted from bacter-
ial cultures as previously described [32]. Briefly, TPGY
broth (Difco, Becton Dickinson and Co., Franklin Lakes,
NJ) was inoculated with isolated C. botulinum bacterial
colonies from each type and incubated anaerobically for
48 hours at 35°C for Group I strains and Group II
strains were grown at 30 C°C followed by low speed
centrifugation harvesting. The pellets were resuspended
in TE and quickly frozen in a dry ice/ethanol bath at
-70°C for three successive cycles followed by melting at
65°C. Sodium dodecylsulfate (SDS) and Proteinase K (10
mg/ml) were added, mixed, and incubated at 42°C for 1
hour. After incubation, 5 M NaCl solution and 10% (w/
v) CTAB (cetyl trimethyl ammonium bromide) solution
were added, mixed thoroughly and incubated at 65°C
for 10 minutes. Following this incubation, three organic
extractions of the mixture were performed using phe-
nol/chloroform/isoamyl alcohol. DNA concentration
w a sm e a s u r e db ys p e c t r o p h o t o m e t r ya n dd i l u t e dt oa
concentration of 25 μg/mL.
Crude Toxin Supernatant Preparation
Isolated colonies from an egg yolk or blood agar plate
that had been incubated for 48 hours in a gas pack jar
Figure 5 qPCR detection of type-specific BoNT DNA in food samples spiked with purified C. botulinum DNA. Canned green beans or
corned beef was spiked with ten-fold dilutions of purified type-specific BoNT DNA. Samples were processed and DNA extracted from each
sample. Results show copy number of each type-specific BoNT dilution in both food types.
Table 5 Detection limits of BoNT DNA in crude toxin
supernatants
Bot A Bot B Bot E Bot F
Crude Toxin 2 ng LOD
Crude Toxin 200 pg LOD LOD
Crude Toxin 20 pg 0.8 (LOD)
Crude Toxin 2 pg
Crude Toxin 200 fg 11.7 2.58
Crude Toxin 20 fg 29.2
LOD indicates the averaged limits of detection for that subtype in our mouse
protection bioassay with identical serotypes used in toxin complex
preparations.
Indicated in this table is the sensitivity of quantitative PCR for type-specific
BoNT detection. Crude toxin supernatants with equivalent toxin protein
amounts are listed. Values included in this table are the exact copy number of
BoNT DNA detected in crude toxin preparations at the indicated amounts of
protein. LOD indicates the averaged limits of detection for that subtype in our
mouse protection bioassay with identical serotypes used in toxin complex
preparations.
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Page 11 of 16were inoculated in ten mL of TPGY broth, (5% Trypti-
case, 0.5% Bacto Peptone, 2% Yeast extract, 0.4% glu-
cose and 0.2% Cystene). The TPGY broth was then
incubated for 5 days at 35°C for proteolytic cultures
and 30°C for non-proteolytic cultures in a gas pack jar.
Samples were then centrifuged at 4000 rpm for 15
minutes and supernatant was filtered through a 0.22
μm membrane filter. Aliquots were made and stored at
-70°C until needed. Sample sterility was tested on
blood agar plates that were incubated for 48 hrs then
checked for growth.
DNA extraction from spiked food, healthy infant stool,
crude toxin samples and infant botulism clinical sample
Canned vegetables and meat from a local market and
stool from a healthy infant were separated into aliquots
of 200 mg amounts of material. Each solid aliquot was
homogenized using a mortar and pestle into a paste. 100
μL of purified DNA from specific C. botulinum strains
was added to the food or stool paste at dilutions ranging
from 10
5 to 10 genomic copies. DNA from each sample
was then extracted using Qiagen’s QiAMP DNA stool
mini kit (Qiagen, Valencia CA) using manufacturer’s
Table 6 Detection of BoNT DNA from purified DNA of bacterial cultures or extracted DNA from crude toxin
supernatants
BoNT A BoNT B BoNT C BoNT D BoNT E BoNT F BoNT G
BoNT subtype strain ABI LC ABI LC ABI LC ABI LC ABI LC ABI LC ABI LC
A1 Hall ++++ +++
A2b CDC 1436 ++ ++++ +++
A3 Loch Maree ++ ++++
B1 Okra ++++ +++
B2 213B ++++ ++
B2 CDC 1828 ++++ +++
B3 CDC 795 +++ +++
B4 (npB) Eklund 17B ++ +++
Ba4 CDC 657 + + +++ +++
Bf An436 +++ +++ ++ +++
C Stockholm ++++ +++
C/D 6813 ++ ++ ++
D ATCC 11873 ++ +++
D/C VPI 5995 ++ ++++ +++
E1 Beluga ++++ ++
E2 CDC 5247 ++++ ++
E2 CDC 5906 +++ ++
E3 Alaska E43 ++++ +++
E4 (It butyr) BL5262 +++ ++
F1 (prot) Langeland ++++ +++
F2 (np) Eklund 202F +++ ++
F3 (baratii) Orange ++
G 1354 ++++ +++
C.sporogenes - - - -----------
10
6 standard ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++
10
5 standard ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++
10
4 standard +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
10
3 standard +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
10
2 standard +++ +++ +++ +++ +++ ++ +++ +++ +++ +++ +++ +++ +++ ++
negative - - - -----------
ABI = Extracted DNA run on an ABI 7700 real time PCR sequence detector.
LC- = Crude C. botulinum culture supernatants run on the Roche Light Cycler. 0-20 cycles = ++++,
21-30 cycles = +++, 31-40 cycles = ++, > 41 cycles = +.
Listed in this table are all strains tested by quantitative PCR for type-specific BoNT. All serotype primer and probe sets were tested against all strains indicated.
Standards indicate the plasmid standards used to determine the quantity of BoNT DNA in each sample. Strains tested on the ABI 7700 machine (ABI) included
purified DNA from bacterial cultures while samples tested by the Roche Light Cycler (LC) were from crude toxin supernatants.
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Page 12 of 16recommendations with one modification. Each sample
was bound to the column provided in the kit and washed
t w i c eb e f o r ep r o c e e d i n gt of u r t h e rs t e p st oe n s u r ee l i m i -
nation of any protein debris that may interfere with sub-
sequent PCR analysis. For crude toxin supernatants,
DNA was extracted from 200 μLo fc r u d es u p e r n a t a n t
using the QiAmp DNA stool mini kit as described above.
For spiked food, healthy infant stool samples and crude
supernatants, extracted DNA was eluted in 50 μLo fe l u -
tion buffer and immediately tested for presence of either
NTNH or type-specific BoNT. NTNH assays were done
on DNA extracted from crude culture supernatants, as
outlined above. The BoNT serotype-specific assays were
done on crude culture supernatants with no further
extraction or processing. Infant stool DNA from a clini-
cal sample was extracted with the MagNA Pure compact
instrument and Nucleic Acid Isolation Kit I (Roche
Applied Science) according to the manufacturer
instructions.
Universal PCR primer designed for NTNH
Sequences used to design a set of universal PCR primers
were obtained from Genbank. All sequences were
aligned with MegAlign (DNASTAR, Lasergene, Inc.).
Both Primer Express (Applied Biosystems, Foster City,
CA) and Primer3 (http://frodo.wi.mit.edu/primer3/),
Table 7 BoNT DNA detection in spiked healthy infant
stool and botulism clinical samples
Spiked healthy infant stool BoNT A + 5525
BoNT B + 7179
BoNT C + 234
BoNT D + 187
BoNT E + 4043
BoNT F + 604
BoNT G + 219
None -
Stool sample from clinical infant botulism case BoNT A + 1650
BoNT B -
BoNT C -
BoNT D -
BoNT E -
BoNT F -
BoNT G -
DNA extracted samples were tested by real time quantitative PCR (qPCR) for
detection and copy number of each BoNT serotype. Shown are results from
approximately 10
4 genomic copies of DNA into each spiked sample prior to
DNA extraction. (+) indicates a positive result with BoNT DNA copy number
indicated in brackets. (-) indicates no amplification.
Listed in this table are the three conditions we tested for serotype-specific
BoNT DNA from spiked healthy infant stool and a clinical sample of a
confirmed case of infant botulism. For healthy infant stool, shown are results
from samples spiked with BoNT DNA with 10
4 genomic equivalents. The
clinical sample was run without dilution. (+) indicates a positive result and the
copy number calculated from standard curves specific to each serotype is
indicated in brackets. (-) indicates no amplification.
Table 8 Bacterial strains tested in PCR
serotype toxin type produced strain
C. botulinum A A1 Hall
C. botulinum A A1 CDC 1757 (infant)
C. botulinum A A1 CDC 1744 (infant)
C. botulinum A A2 Kyoto-F (infant)
C. botulinum Ab A2b CDC 1436 (infant)
C. botulinum A A3 Loch Maree
C. botulinum B B1 Okra
C. botulinum B B1 CDC 1656 (infant)
C. botulinum B B1 CDC 1758 (infant)
C. botulinum B B2 213B
C. botulinum B B2 CDC 1828 (infant)
C. botulinum B B3 CDC 795
C. botulinum B B4 (npB) Eklund 17B
C. botulinum Ba Ba4 CDC 657 (infant)
C. botulinum Bf Bf An436 (infant)
C. botulinum C C Stockholm
C. botulinum C C/D 6813
C. botulinum D D ATCC 11873
C. botulinum D D 1873
C. botulinum D D/C VPI 5995
C. botulinum E E1 Beluga
C. botulinum E E2 CDC 5247
C. botulinum E E2 CDC 5906
C. botulinum E E3 Alaska E43
C. butyricum E E4 BL5262 (infant)
C. botulinum F F1 (prot) Langeland
C. botulinum F F2 (np) Eklund 202F
C. baratii F F3 Orange
C. botulinum G G 1354
C. absonum ATCC 27555
C. baratii ATCC 27638
C. bifermentans ATCC 638
C. haemolyticum ATCC 9650
C. hastiforme ATCC 25772
C. histolyticum histolyticum a, b ATCC 19401
C. novyi ATCC 17861
C. novyi ATCC 19402
C. novyi A novyi a, g, ε ATCC 19402
C. novyi B novyi a, b ATCC 2706
C. perfringens A perfringens a ATCC 3624
C. perfringens A perfringens a ATCC 12915
C. perfringens A perfringens a ATCC 12917
C. perfringens A perfringens a ATCC 12918
C. perfringens A perfringens a ATCC 12919
C. perfringens A perfringens a ATCC 13124
C. perfringens B perfringens a, b, ε ATCC 3626
C. perfringens D perfringens a, ε ATCC 3629
C. perfringens D perfringens a, ε ATCC 3630
C. perfringens D perfringens a, ε ATCC 3631
C. perfringens D perfringens a, ε ATCC 12920
C. perfringens E perfringens a, τ ATCC 27324
Hill et al. BMC Microbiology 2010, 10:267
http://www.biomedcentral.com/1471-2180/10/267
Page 13 of 16were used to design a pair of degenerate primers that
included base differences to detect all known NTNH
gene variants. Primer sequences are designated in Figure
1.
Universal PCR for detection of NTNH of all C. botulinum
types
Purified DNA from C. botulinum, E. coli bacterial DNA
(pUC19 plasmid DNA) or crude lysate from human leu-
kocytes were used in the universal PCR. PCR conditions
were as follows: 95°C for 5 minutes, then 35 cycles of
95°C for 15 seconds and 57°C for 1 minute. PCR reac-
tion mixture contained PCR Buffer, 3.5 uM MgCl2, 200
nM dNTP, 1 uM forward or reverse primer, 0.25 U Taq
Polymerase (Invitrogen Corp, Carlsbad, CA). 5 μLo f
DNA (0.25 ng/uL) was used in each 25 μL PCR reac-
tion. PCR products were run on a 2.5% agarose gel to
separate the product from any non-specific amplification
and visualized for 101 bp bands by UV illumination.
Toxin type-specific qPCR primer and probe design
Neurotoxin gene sequences, obtained both from Gen-
bank and from sequences provided by Biosciences Divi-
sion, Los Alamos National Laboratories, were aligned
and degenerate primer/probe sets were designed using
software packages as above for each toxin type. Each
degenerate primer/probe set include all known base dif-
ferences within each toxin type.
Generation of qPCR standards for each C. botulinum toxin
type-specific assay
Seven samples of purified C. botulinum DNA, one for
each toxin type, were used in the generation of plasmid
DNA standards for qPCR. Briefly, primers designed spe-
cifically for each toxin type were used to amplify a
region of the toxin gene containing the degenerate pri-
mer/probe set target sequences. The PCR conditions
were as follows: 95°C for 5 minutes, then 35 cycles of
95°C for 15 seconds and 60°C for 1 minute. PCR
reaction mixture contained PCR Buffer, 3.5 uM MgCl2,
200 nM dNTPs, 500 nM forward or reverse primer, 0.25
U Taq Polymerase (Invitrogen). 5 μLo fD N A( 0 . 2 5n g /
uL) was used in each 25 μL PCR reaction. PCR products
were visualized by UV on a 1.5% agarose gel. Corre-
sponding specific products were gel purified and ligated
into pGEM T-easy vector (Promega Corp., Madison,
WI). Ligations were transformed into DH5a E.coli bac-
teria using a-complementation to determine positive
colonies. Positive colonies were grown in overnight cul-
t u r e s ,p l a s m i dD N Aw a sp u r i f i e da n ds e q u e n c e df o r
determination of correct subtype insert sequence. DNA
was quantified by UV spectrophotometry and serial dilu-
tions of plasmid standard were made from 10
6 to 10
2
target molecules/5 μL.
qPCR for BoNT Type-Specific Detection
The qPCR assay consisted of seven separate reactions,
each specific for one of the seven neurotoxin gene types.
For absolute quantification, template standards for each
of the neurotoxin gene types were run alongside the
DNA samples for each of the seven qPCRs. qPCR condi-
tions were as follows: 95°C for 5 minutes, then 45 cycles
of 95°C for 15 seconds and 60°C for 1 minute. PCR
reaction mixture contained PCR Buffer, 3.5 uM MgCl2,
200 nM dNTPs, 500 nM forward or reverse primer, 200
nM Fam/BHQ1-labeled probe, 3 nM BD636 reference
dye, 0.25 U Taq Polymerase (Invitrogen Corp, Carlsbad,
CA). 5 μLo fp u r i f i e dD N Ao rp l a s m i ds t a n d a r dw a s
used in each 25 μL PCR reaction. Based on cycle of
threshold (Ct) values with known copy numbers of plas-
mid in each reaction, a standard curve is generated that
will be used to calculate the values of unknown samples.
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Table 8: Bacterial strains tested in PCR (Continued)
C. ramosum ATCC 25582
C. septicum septicum a ATCC 12464
C. sordelli ATCC 9714
C. sporogenes ATCC 19404
C. sporogenes ATCC3854
C. subterminale ATCC 25774
C. tertium ATCC 14573
C. tetani tetanus ATCC 10799
C. tetani tetanus ATCC19406
The C. botulinum and BoNT E-producing C. butyricum strains are from the
USAMRIID.
C. botulinum culture collection, which forms part of the Unified Culture
Collection.
The other Clostridium species were obtained from ATCC.
All clostridial species tested in these studies are listed with strain
identifications. Where applicable toxin serotype and/or toxin types are shown.
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